<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00327600</url>
  </required_header>
  <id_info>
    <org_study_id>AMP-005</org_study_id>
    <nct_id>NCT00327600</nct_id>
    <nct_alias>NCT00301132</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma</brief_title>
  <official_title>A Phase 1/2 Trial of AmplimexonÂ® (Imexon, Inj.) Plus Dacarbazine (DTIC) in Chemotherapy Naive Patients With Unresectable Stage III or Stage IV Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AmpliMed Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AmpliMed Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AMP-005 is a Phase 1b/2 clinical trial designed to evaluate whether the new drug, imexon, can
      be administered in combination with the approved drug, dacarbazine (DTIC), for the treatment
      of patients with stage III or IV inoperable melanoma. The Phase 1b part of the study is
      designed to determine whether the two drugs can be safely combined together, and the Phase 2
      part of the study is designed to provide additional safety data and to gain an understanding
      of whether adding imexon to DTIC can improve the outcome for melanoma patients versus the
      findings from prior clinical studies of DTIC alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximally tolerated dose of imexon plus DTIC</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>determine the toxicity and tolerability of the combination</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>determine response rate and progression free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine effects of the drug combination on plasma thiol levels and other biomarkers</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>imexon + DTIC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imexon</intervention_name>
    <arm_group_label>imexon + DTIC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTIC</intervention_name>
    <arm_group_label>imexon + DTIC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Malignant melanoma; inoperable stage III or IV disease.

          -  Able to perform the activities of daily living.

          -  A projected life expectancy of at least 4 months.

          -  If female, neither pregnant nor nursing.

          -  Willing to use contraceptives to prevent pregnancy.

          -  Blood cell counts and blood chemistries in or near normal range.

          -  Prior radiation is permitted.

          -  No other serious illnesses.

          -  No other active malignancy.

          -  No serious infections.

          -  No other current drug therapy for the cancer or steroid therapy.

        Exclusion Criteria:

          -  No prior chemotherapy for the stage III or IV disease.

          -  Brain metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Hersh, MD</last_name>
    <role>Study Director</role>
    <affiliation>AmpliMed Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site 009</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 002</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of CO Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology Orlando, Cancer Centers of FL</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology Albany, New York Oncology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology Kettering</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology Greenville, Cancer Centers of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology, Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 012</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology, Virginia Oncology Assoc</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology Spokane, Cancer Care Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O'Day S, Sato T, Dorr R, Grenier K, Hersh E. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 2010 Aug 1;116(15):3683-91. doi: 10.1002/cncr.25119.</citation>
    <PMID>20564083</PMID>
  </results_reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2006</study_first_submitted>
  <study_first_submitted_qc>May 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2006</study_first_posted>
  <last_update_submitted>September 14, 2010</last_update_submitted>
  <last_update_submitted_qc>September 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Evan Hersh, VP Medical Affairs</name_title>
    <organization>AmpliMed Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

